SmallCapReview.com has been a leading site for information on small cap stocks and penny stocks since 1999, to receive the free SmallCapReview newsletter visit http://www.smallcapreview.com.
American Superconductor Corporation (Nasdaq: AMSC) $42.15. Today announced that its wholly-owned AMSC Windtec subsidiary has signed a follow-on contract with Dongfang Turbine Co. Ltd. to design and jointly develop 5 megawatt (MW) full conversion wind turbines for the offshore wind power market.
Dongfang is one of China’s top machinery companies. The company entered the wind power market in 2004 and shipped more than 800 wind turbines with a 1.5 MW power rating in 2008, making it the country’s third largest wind turbine manufacturer.
What They Do: AMSC offers an array of proprietary technologies and solutions spanning the electric power infrastructure – from generation to delivery to end use.
PATTERSON-UTI ENERGY (Nasdaq: PTEN) $16.19. Today announced that for the month of December 2009, the Company had an average of 118 drilling rigs operating, including 108 rigs in the United States and 10 rigs in Canada. For the three months ended December 2009, the Company had an average of 103 drilling rigs operating, including 95 rigs in the United States and 8 rigs in Canada.
What They Do: Patterson-UTI Energy, Inc. provides onshore contract drilling services to exploration and production companies in North America.
Geron Corporation (Nasdaq: GERN) $6.22. Today announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, imetelstat (GRN163L), inhibited telomerase activity and reduced tumor size in xenograft models of glioblastoma, and inhibited the activity of glioblastoma stem cells in culture.
The data, authored by Geron collaborators at the University of Texas Southwestern Medical Center at Dallas, were published in the January 1, 2010 issue of Clinical Cancer Research.
“We are excited by the telomerase inhibition observed in the glioblastoma model. The blood-brain tumor barrier limits the delivery of most therapeutic drugs to brain tumors, but these data show that imetelstat penetrates that barrier,” said Thomas B. Okarma, Ph.D., M.D., Geron's president and chief executive officer. “Cancer stem cells pose an additional therapeutic challenge. These data add to the growing list of cancer types where the inhibition of cancer stem cells by imetelstat has been shown preclinically. We will further investigate imetelstat’s anti-cancer stem cell potential clinically in our Phase II trials in breast and lung cancers, multiple myeloma and chronic leukemias that will begin later this year.”
What They Do: Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com/. To follow us on Twitter visit http://twitter.com/SmallCapReview.
